Ahu Demir

Jonathan Aschoff

- Cyclacel Pharmaceuticals, Inc. issued amended and restated Series A, B, and C common stock purchase warrants on **September 1, 2025**.  **[1130166_0001641172-25-026110_form8-k.htm:1]** **[1130166_0001641172-25-026110_ex10-1.htm:0]** **[1130166_0001641172-25-026110_ex10-2.htm:0]** **[1130166_0001641172-25-026110_ex10-3.htm:0]** 
- The primary amendment is the **removal of the Ownership Limitation**, which previously restricted holders from exercising warrants if it resulted in ownership exceeding a certain percentage (e.g., **4.99%**) without a stockholder vote.  **[1130166_0001641172-25-026110_form8-k.htm:1]** 
- This removal was approved by the company's Board of Directors and majority stockholders, effective **July 28, 2025**.  **[1130166_0001641172-25-026110_form8-k.htm:1]** 
- Each series (A, B, and C) of the amended warrants entitles the holder to purchase **218,000** shares of common stock.  **[1130166_0001641172-25-026110_form8-k.htm:1]** **[1130166_0001641172-25-026110_ex10-1.htm:0]** **[1130166_0001641172-25-026110_ex10-2.htm:0]** **[1130166_0001641172-25-026110_ex10-3.htm:0]** 
- The exercise prices are **$7.65** per share for Series A, **$9.00** per share for Series B, and **$10.20** per share for Series C, with all warrants expiring on **June 20, 2030**.  **[1130166_0001641172-25-026110_form8-k.htm:1]** **[1130166_0001641172-25-026110_ex10-1.htm:1]** **[1130166_0001641172-25-026110_ex10-2.htm:1]** **[1130166_0001641172-25-026110_ex10-3.htm:1]** **[1130166_0001641172-25-026110_ex10-1.htm:0]** **[1130166_0001641172-25-026110_ex10-2.htm:0]** **[1130166_0001641172-25-026110_ex10-3.htm:0]**

Cyclacel Pharmaceuticals (CYCC)